申请人:——
公开号:US20020137782A1
公开(公告)日:2002-09-26
The invention is directed to physiologically active compounds of formula (Ia):
1
wherein R
1
is optionally substituted aryl or optionally substituted heteroaryl; R
2
is hydrogen, halogen, lower alkyl or lower alkoxy; R
3
is alkylene, alkenylene or alkynylene; R
5
is hydrogen or lower alkyl; L
2
is optionally substituted alkylene or alkenylene; Y is carboxy; and Z
1
is NR
5
; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.
Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).
该发明涉及式(Ia)的生理活性化合物:
其中R1是可选择取代的芳基或可选择取代的杂环芳基;R2是氢、卤素、低碳基或低烷氧基;R3是烷基、烯基或炔基;R5是氢或低碳基;L2是可选择取代的烷基或烯基;Y是羧基;Z1是NR5;以及相应的N-氧化物,它们的前药;以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化合物(例如水合物)。
这些化合物具有有价值的药理特性,特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4(α4β1)相互作用的能力。